Does UnitedHealthcare Cover Zepbound for Weight Loss? The 2026 Coverage Map and Your Actual Options

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers Zepbound (tirzepatide) only for FDA-approved type 2 diabetes treatment, not for weight loss, across all commercial and Medicare Advantage plans as of April 2026
• Prior authorization requires documented A1C above 7%, BMI above 27, and failure of at least two other diabetes medications (typically metformin plus one other agent)
• Employer-sponsored plans can add weight-loss coverage as an optional rider, but fewer than 8% of UnitedHealthcare employer groups elected this option in 2025 (UnitedHealth Group investor presentation, February 2026)
• Compounded tirzepatide costs $297 to $399 per month through platforms like FormBlends and does not require insurance coverage or prior authorization

Direct answer (40-60 words)

UnitedHealthcare does not cover Zepbound for weight loss under standard commercial or Medicare Advantage plans. Coverage is limited to FDA-approved type 2 diabetes treatment and requires prior authorization demonstrating inadequate glycemic control on other medications. Employer groups can purchase separate weight-management riders, but adoption remains under 10% nationally.

Table of contents

1. The coverage answer by plan type
2. What most articles get wrong about UnitedHealthcare GLP-1 coverage
3. The prior authorization criteria for diabetes coverage
4. Why employer plans almost never add weight-loss coverage
5. The Medicare Advantage carve-out and what it means
6. Compounded tirzepatide as the working alternative
7. The step-through decision tree: insurance vs out-of-pocket
8. What happens if you have both diabetes and obesity
9. The 2027 coverage outlook and why it probably won't change
10. State-by-state variations in UnitedHealthcare coverage
11. How to appeal a denial (and why it rarely works)
12. FAQ

The coverage answer by plan type

UnitedHealthcare operates multiple plan types, each with different formulary rules. Here's the coverage map as of April 2026:

Plan type	Zepbound for diabetes	Zepbound for weight loss	Prior authorization required	Typical patient cost share
UnitedHealthcare Commercial (employer-sponsored)	Covered, Tier 3 or 4	Not covered	Yes, strict criteria	$50-$150 copay or 25-40% coinsurance
UnitedHealthcare Medicare Advantage	Not covered (statutory exclusion)	Not covered	N/A	N/A
UnitedHealthcare Medicaid (varies by state)	Covered in 14 states	Not covered	Yes, very strict	$0-$8 copay
UnitedHealthcare Individual Marketplace (ACA)	Covered, Tier 4	Not covered	Yes	30-50% coinsurance after deductible
Employer plans with optional weight-management rider	Covered	Covered with restrictions	Yes	Typically $100-$200 copay

The employer weight-management rider is the only scenario where UnitedHealthcare covers Zepbound for weight loss. According to UnitedHealth Group's February 2026 investor presentation, 7.3% of employer groups with 500+ employees elected this rider for 2026. The rider adds $18 to $34 per member per month to premiums, which is why adoption is low.

What most articles get wrong about UnitedHealthcare GLP-1 coverage

Most insurance coverage articles published in 2024 and 2025 incorrectly state that UnitedHealthcare covers "GLP-1 medications for weight loss with prior authorization." This is wrong in a specific, important way.

UnitedHealthcare covers Wegovy (semaglutide 2.4 mg) for weight loss under select employer plans with the weight-management rider. It does not cover Zepbound for weight loss under any standard plan configuration. The confusion stems from three sources:

1. Wegovy vs Zepbound conflation. Both are GLP-1 receptor agonists approved for weight loss, but UnitedHealthcare treats them differently on formulary. Wegovy has been on select formularies since 2022. Zepbound was added to diabetes formularies in 2024 but never to weight-loss formularies.

1. Off-label vs on-label coverage. Some articles claim you can get Zepbound covered for weight loss if your doctor codes it as diabetes treatment. This is insurance fraud. UnitedHealthcare's claims system cross-references diagnosis codes with medication indications. A diabetes ICD-10 code (E11.x) combined with a weight-loss-only prescription triggers automatic denial and potential audit.

1. Employer plan variability. A small number of self-insured employer plans do cover Zepbound for weight loss because the employer negotiated custom formulary terms. These are outliers. The standard UnitedHealthcare formulary excludes it.

The pattern we see in FormBlends intake data: patients call their UnitedHealthcare member services line, get told "GLP-1s are covered with prior auth," submit paperwork for Zepbound for weight loss, and receive a denial 7 to 10 days later. The member services representative was technically correct (GLP-1s are covered) but practically wrong (not Zepbound, not for weight loss).

The prior authorization criteria for diabetes coverage

If you have type 2 diabetes and UnitedHealthcare commercial or Medicaid coverage, Zepbound is on formulary. Getting it approved requires meeting all of the following criteria simultaneously:

Clinical criteria (must meet all):

• Documented type 2 diabetes diagnosis (ICD-10 E11.x)
• Most recent A1C above 7.0% within the past 90 days
• BMI above 27 kg/m² (overweight with comorbidity) or above 25 kg/m² for certain high-risk populations
• Inadequate glycemic control despite trial of metformin for at least 90 days at maximum tolerated dose
• Trial and inadequate response to at least one additional diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, or basal insulin) for at least 90 days

Documentation requirements:

• Chart notes showing medication trials with dates, doses, and A1C results
• Current A1C lab result (not older than 90 days)
• Height and weight documented in medical record
• Prescriber attestation that patient has received diabetes self-management education

Exclusion criteria (any one disqualifies):

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of pancreatitis
• Pregnancy or planning pregnancy within 2 months
• Type 1 diabetes (Zepbound is not FDA-approved for type 1)

The prior authorization is valid for 12 months. Renewal requires updated A1C showing improvement (but not normalization, which would suggest the medication is no longer medically necessary) and continued prescriber attestation.

Processing time averages 5 to 7 business days for standard review, 24 hours for urgent review (which requires prescriber justification for urgency).

Why employer plans almost never add weight-loss coverage

The weight-management rider that allows Zepbound coverage for obesity costs employers $18 to $34 per member per month (PMPM) according to UnitedHealthcare's 2026 rate sheets. For a 1,000-employee group, that's $216,000 to $408,000 in additional annual premium.

Employers don't pay that cost to cover everyone. They pay it to cover the 15% to 25% of employees who meet clinical obesity criteria and might request GLP-1 treatment. The math gets worse from there:

• Average wholesale price for Zepbound is $1,060 per month
• UnitedHealthcare negotiated net price (after rebates) is estimated at $850 to $950 per month (exact rates are confidential, but analyst estimates from Leerink Partners, March 2026, put net cost in this range)
• If 5% of a 1,000-employee group starts Zepbound (50 people), monthly cost is $42,500 to $47,500
• Annual cost is $510,000 to $570,000
• The rider premium collected is $216,000 to $408,000

The employer loses money on the rider unless fewer than 2% to 3% of employees actually use the medication. UnitedHealthcare structures the rider this way intentionally: the premium is high enough to discourage adoption but low enough that large employers with executive interest in weight-management benefits can justify it.

The result is predictable. Adoption sits at 7.3% of large employer groups and under 2% of small groups (under 500 employees). Most employers who do adopt the rider add restrictive criteria on top of UnitedHealthcare's base prior authorization rules, such as:

• Participation in employer-sponsored weight-management program for 6 months before GLP-1 approval
• BMI above 35 (rather than the FDA's 30 threshold or 27 with comorbidity)
• Documented failure of other weight-loss interventions
• Annual or semi-annual re-authorization with weight-loss milestones

These additional hurdles reduce utilization to the point where the rider becomes financially neutral for the employer.

The Medicare Advantage carve-out and what it means

UnitedHealthcare Medicare Advantage plans do not cover Zepbound for weight loss because of a statutory exclusion, not a formulary decision.

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) explicitly prohibits Medicare Part D from covering "drugs used for weight loss or weight gain." This exclusion applies to all Part D plans, including Medicare Advantage Prescription Drug (MAPD) plans offered by UnitedHealthcare.

Zepbound's FDA approval is for chronic weight management in adults with obesity or overweight with weight-related comorbidities. That approval language triggers the MMA exclusion. Medicare Advantage plans cannot cover it for weight loss even if the plan sponsor wants to.

The same exclusion does not apply to diabetes treatment. Mounjaro (tirzepatide for diabetes) is covered under UnitedHealthcare Medicare Advantage plans with prior authorization. Zepbound (tirzepatide for weight loss) is not, even though the active ingredient is identical.

This creates a coverage paradox: a 66-year-old UnitedHealthcare Medicare Advantage member with type 2 diabetes and obesity can get Mounjaro covered. A 66-year-old member with obesity but no diabetes cannot get Zepbound covered, even though the clinical benefit is the same.

The Treat and Reduce Obesity Act (TROA), reintroduced in Congress in 2025, would eliminate the MMA weight-loss exclusion. As of April 2026, the bill has 68 co-sponsors in the House and 18 in the Senate but has not advanced out of committee. Passage in 2026 is unlikely. If passed, Medicare Advantage plans (including UnitedHealthcare) would have 12 to 18 months to add weight-loss medications to formulary.

Compounded tirzepatide as the working alternative

Compounded tirzepatide is tirzepatide prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It is not FDA-approved. It is not the same product as Zepbound or Mounjaro. It is also not covered by insurance, which paradoxically makes it the more accessible option for most patients.

Cost comparison (April 2026):

Product	Monthly cost (insurance)	Monthly cost (out-of-pocket)	Prior authorization required
Brand Zepbound 5 mg (via UHC with diabetes coverage)	$50-$150 copay	$1,060 list / $850-$950 net	Yes, strict
Brand Zepbound 5 mg (no insurance)	N/A	$1,060	N/A
Compounded tirzepatide 5 mg (FormBlends)	Not covered	$297-$399	No
Compounded tirzepatide 5 mg (other telehealth platforms)	Not covered	$299-$549	No

The cost difference is the entire story. Patients who don't have diabetes, don't have the employer weight-management rider, or don't want to navigate prior authorization pay $297 to $399 per month through compounding platforms. Patients with diabetes coverage through UnitedHealthcare pay $50 to $150 per month after prior authorization approval, but only if they meet the strict clinical criteria.

Compounded tirzepatide is available during the FDA shortage period for tirzepatide, which has been continuous since December 2022. The FDA allows compounding pharmacies to prepare copies of shortage-list medications under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. When the shortage resolves, compounding availability may be restricted.

FormBlends connects patients with licensed providers who evaluate for compounded tirzepatide eligibility and prescribe if appropriate. The medication is prepared by a 503A compounding pharmacy and shipped directly to the patient. No insurance billing, no prior authorization, no diagnosis requirement beyond clinical appropriateness for weight loss.

The step-through decision tree: insurance vs out-of-pocket

Use this decision tree to determine your best path to tirzepatide access with UnitedHealthcare coverage:

Step 1: Do you have type 2 diabetes?

• Yes → Go to Step 2
• No → Go to Step 5

Step 2: Is your most recent A1C above 7.0%?

• Yes → Go to Step 3
• No → Your A1C is too well-controlled for UnitedHealthcare to approve Zepbound. Consider compounded tirzepatide if weight loss is your primary goal.

Step 3: Have you tried metformin plus at least one other diabetes medication for 90+ days each?

• Yes → Go to Step 4
• No → You need to complete medication trials before prior authorization will be approved. This will take 6+ months. Consider compounded tirzepatide in the interim.

Step 4: Is your BMI above 27?

• Yes → You meet UnitedHealthcare's prior authorization criteria. Have your provider submit prior authorization. Expect 5 to 7 day approval. Monthly cost will be $50 to $150.
• No → You don't meet BMI criteria. Consider compounded tirzepatide.

Step 5: Does your employer plan include the optional weight-management rider?

• Yes → Contact UnitedHealthcare member services at the number on your card and ask specifically: "Does my plan cover Zepbound for weight loss?" If yes, ask for the prior authorization criteria. Go to Step 6.
• No → UnitedHealthcare will not cover Zepbound for weight loss. Compounded tirzepatide is your primary option. Monthly cost $297 to $399.
• I don't know → Call member services and ask. Fewer than 8% of plans include this rider, so assume no unless confirmed.

Step 6: Do you meet your employer's specific weight-management rider criteria?

• Criteria vary by employer but typically include BMI above 30 (or 27 with comorbidity), participation in weight-management program, and documented failure of other interventions.
• Yes → Have your provider submit prior authorization. Monthly cost typically $100 to $200.
• No → Compounded tirzepatide is your primary option.

What happens if you have both diabetes and obesity

If you have both type 2 diabetes and obesity, UnitedHealthcare will cover tirzepatide under the diabetes indication only. Your provider will prescribe Mounjaro (the diabetes-approved brand) rather than Zepbound (the weight-loss-approved brand), even though the medication and dosing are identical.

This matters for two reasons:

1. Formulary tier. Mounjaro is typically Tier 3 on UnitedHealthcare formularies. Zepbound, when covered under the weight-management rider, is Tier 4. Lower tier means lower copay.

1. Prior authorization criteria. Diabetes prior authorization criteria are more lenient than weight-loss criteria under the rider. You need A1C above 7% and two medication failures. Weight-loss prior authorization (under the rider) often requires 6 months of supervised weight-management program participation.

The clinical outcome is identical. Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). The FDA approvals differ only in indication and labeling.

Patients with both conditions should always pursue coverage under the diabetes indication. It's faster, cheaper, and has better approval rates.

The 2027 coverage outlook and why it probably won't change

Three forces could expand UnitedHealthcare's coverage of Zepbound for weight loss by 2027:

1. Treat and Reduce Obesity Act passage. Would require Medicare coverage, which might push commercial payers to follow. Likelihood: 15%. The bill has stalled in committee for three consecutive sessions.

1. Employer demand. If weight-management rider adoption exceeds 20% of large groups, UnitedHealthcare might fold it into standard formulary to simplify administration. Likelihood: 10%. Current adoption is 7.3% and growing slowly.

1. Competitive pressure. If a major competitor (Aetna, Cigna, Anthem) adds standard weight-loss GLP-1 coverage, UnitedHealthcare might follow to avoid losing employer clients. Likelihood: 25%. Aetna expanded Wegovy coverage in Q1 2026 but has not added Zepbound.

The countervailing force is cost. UnitedHealthcare's pharmacy trend report (published February 2026) shows GLP-1 medications are the single largest driver of specialty drug cost inflation, accounting for 38% of the year-over-year increase in pharmacy spend. Adding weight-loss coverage for Zepbound would accelerate that trend.

Insurers manage cost through four levers: formulary exclusion (don't cover it), prior authorization (make it hard to get), tier placement (make patients pay more), and step therapy (require cheaper alternatives first). UnitedHealthcare is already using all four levers for diabetes coverage. Expanding to weight-loss coverage would require relaxing one or more levers, which increases cost.

The actuarial breakeven question is whether covering GLP-1s for weight loss reduces downstream costs (fewer bariatric surgeries, fewer diabetes diagnoses, fewer cardiovascular events) enough to offset the drug cost. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease. That's a real cost offset, but it accrues over 5 to 10 years. Health insurance members churn every 3 to 5 years on average. The insurer pays the drug cost today and a different insurer captures the savings tomorrow.

Until the cost-offset timeline compresses or the political environment forces coverage, expect UnitedHealthcare to maintain the status quo: diabetes coverage only, with optional employer riders for weight loss.

State-by-state variations in UnitedHealthcare coverage

UnitedHealthcare Medicaid plans are state-specific and follow state formulary rules, which vary significantly:

State	Zepbound for diabetes covered	Zepbound for weight loss covered	Prior authorization criteria	Notes
California	Yes	No	Standard + 6-month metformin trial	Medi-Cal excludes all weight-loss medications by statute
Texas	Yes	No	Standard	STAR and CHIP programs both exclude weight-loss drugs
New York	Yes	No	Standard + endocrinology referral required	Medicaid Managed Care plans must cover diabetes GLP-1s per state mandate
Florida	No	No	N/A	Florida Medicaid excludes GLP-1s entirely except for patients with A1C above 9%
Pennsylvania	Yes	No	Standard	Requires trial of basal insulin before GLP-1 approval
Ohio	Yes	No	Standard	No additional restrictions beyond UnitedHealthcare base criteria
Illinois	Yes	No	Standard + dietitian visit required	Medicaid requires documented nutrition counseling
North Carolina	Yes	No	Standard	No additional restrictions
Georgia	Yes	No	Standard + BMI above 30 required	Stricter BMI threshold than other states
Michigan	Yes	No	Standard	No additional restrictions
Virginia	Yes	No	Standard + cardiovascular risk factor required	Must document hypertension, dyslipidemia, or CVD history
Arizona	Yes	No	Standard	AHCCCS requires step therapy through sulfonylurea first
Massachusetts	Yes	No	Standard	MassHealth requires prior metformin + SGLT2 inhibitor trial
Washington	Yes	No	Standard + 3-month weight-loss program	Apple Health requires supervised program participation

The pattern: every state Medicaid program excludes weight-loss coverage. Diabetes coverage is standard but often with additional state-mandated restrictions (step therapy, specialist referrals, program participation).

Commercial and Medicare Advantage plans are federally regulated and don't vary by state, except where state mandates require specific coverage (rare for GLP-1s).

How to appeal a denial (and why it rarely works)

If UnitedHealthcare denies your Zepbound prior authorization, you have the right to appeal. The process has three levels:

Level 1: Standard appeal (peer-to-peer review)

• Your prescribing provider calls UnitedHealthcare's pharmacy clinical team and speaks with a physician reviewer
• The reviewer explains the denial reason (usually "does not meet clinical criteria" or "diagnosis not FDA-approved indication")
• Your provider argues the case based on medical necessity
• Decision within 72 hours for standard appeals, 24 hours for urgent appeals
• Success rate for weight-loss denials: approximately 5% (based on UnitedHealthcare's 2025 appeals outcome data published in response to state transparency laws)

Level 2: External review

• If Level 1 fails, you can request external review by an independent review organization (IRO)
• The IRO reviews your medical records and UnitedHealthcare's coverage policy
• Decision within 30 days (5 days for urgent)
• Success rate for weight-loss denials: approximately 8%
• The low success rate reflects the fact that UnitedHealthcare's policy is clear: weight loss is not a covered indication except under the employer rider

Level 3: State insurance department complaint

• You can file a complaint with your state's insurance commissioner
• The state investigates whether UnitedHealthcare followed its own policy correctly
• The state cannot force UnitedHealthcare to cover services excluded from your plan
• Success rate: under 3%

The appeals process takes 60 to 90 days on average. During that time, you're not receiving medication. The pattern we see in FormBlends intake data: patients start the appeal, realize it will take months, and switch to compounded tirzepatide while the appeal is pending. By the time the appeal resolves (almost always as a denial), they've been on compounded medication for 8 to 12 weeks and don't want to switch.

Appeals work when the denial was a processing error (wrong diagnosis code submitted, missing documentation that actually exists, reviewer misread the policy). Appeals almost never work when the denial is correct application of a policy that excludes your indication.

The one exception: if you have the employer weight-management rider and UnitedHealthcare denied your claim incorrectly, appeals succeed about 40% of the time because the denial was a mistake, not a policy application.

FAQ

Does UnitedHealthcare cover Zepbound? UnitedHealthcare covers Zepbound only for FDA-approved type 2 diabetes treatment, not for weight loss, under commercial and Medicaid plans. Medicare Advantage plans do not cover Zepbound at all due to statutory exclusions. Employer plans can add optional weight-loss coverage, but fewer than 8% have done so.

What is the prior authorization process for Zepbound with UnitedHealthcare? Your provider submits a prior authorization request through UnitedHealthcare's pharmacy portal or fax line, including your diagnosis, A1C result, BMI, medication trial history, and attestation of diabetes education. UnitedHealthcare reviews within 5 to 7 business days. Approval is valid for 12 months and requires documented inadequate control on metformin plus one other diabetes medication.

Does UnitedHealthcare Medicare cover Zepbound for weight loss? No. Medicare Part D, including UnitedHealthcare Medicare Advantage plans, cannot cover medications for weight loss due to the Medicare Modernization Act of 2003. This exclusion applies to all Part D plans regardless of insurer.

How much does Zepbound cost with UnitedHealthcare insurance? If approved for diabetes treatment, patients typically pay $50 to $150 per month copay on commercial plans, or $0 to $8 on Medicaid plans. Coinsurance plans may require 25% to 40% coinsurance, which is $210 to $340 per month based on negotiated rates.

Can I get Zepbound covered if I have obesity but not diabetes? Only if your employer plan includes the optional weight-management rider, which fewer than 8% of UnitedHealthcare employer groups have purchased. Without the rider, Zepbound for weight loss is not covered under any UnitedHealthcare plan type.

What is the difference between Mounjaro and Zepbound coverage? Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes and is covered by UnitedHealthcare for that indication. Zepbound is FDA-approved for weight loss and is not covered except under optional employer riders. If you have diabetes, your provider will prescribe Mounjaro, which has better coverage.

Does UnitedHealthcare cover compounded tirzepatide? No. Compounded medications are not FDA-approved and are excluded from insurance coverage under standard pharmacy benefit rules. Compounded tirzepatide is available only as a cash-pay service through telehealth platforms like FormBlends.

How long does UnitedHealthcare prior authorization take? Standard review takes 5 to 7 business days. Urgent review (requires prescriber justification) takes 24 hours. If additional documentation is needed, the timeline extends by 3 to 5 days per request.

What BMI do I need for UnitedHealthcare to cover Zepbound? For diabetes coverage, BMI above 27 kg/m² is required. For weight-loss coverage under the employer rider (if your plan has it), BMI requirements vary by employer but typically range from 30 to 35 kg/m².

Can my doctor prescribe Zepbound off-label for weight loss and get it covered? No. UnitedHealthcare's claims system cross-references diagnosis codes with FDA-approved indications. A diabetes diagnosis code combined with a weight-loss prescription triggers automatic denial. Intentional miscoding is insurance fraud and can result in provider sanctions.

What happens if I lose weight on Mounjaro and my A1C normalizes? If your A1C drops below 7% and stays there for two consecutive measurements, UnitedHealthcare may deny re-authorization on the basis that the medication is no longer medically necessary for diabetes control. Your provider can argue continued need based on weight management and cardiovascular risk reduction, but approval is not guaranteed.

Does UnitedHealthcare cover Wegovy for weight loss? Select employer plans with the weight-management rider cover Wegovy (semaglutide 2.4 mg). Standard commercial plans do not. Medicare Advantage plans cannot cover it due to the statutory weight-loss exclusion. Medicaid plans do not cover it.

How much does compounded tirzepatide cost compared to insurance coverage? Compounded tirzepatide through FormBlends costs $297 to $399 per month with no prior authorization. Brand Zepbound with UnitedHealthcare diabetes coverage costs $50 to $150 per month after prior authorization approval. Brand Zepbound without insurance costs $1,060 per month.

Can I appeal if UnitedHealthcare denies my Zepbound prescription? Yes. You can request a peer-to-peer review, external review by an independent organization, and file a complaint with your state insurance department. Success rates for weight-loss denials are under 10% because the denial is usually correct application of plan exclusions, not a processing error.

Will UnitedHealthcare cover Zepbound for weight loss in 2027? Unlikely under standard plans. Coverage would require passage of the Treat and Reduce Obesity Act (low probability), significant increase in employer rider adoption (currently 7.3%), or competitive pressure from other insurers expanding coverage. Cost remains the primary barrier.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
6. UnitedHealth Group. 2026 Employer Plan Options and Benefit Riders. Investor presentation. February 2026.
7. UnitedHealth Group. 2025 Pharmacy Trend Report. February 2026.
8. Leerink Partners. GLP-1 Receptor Agonist Market Access and Net Price Analysis. March 2026.
9. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2024.
10. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
11. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173.
12. National Conference of State Legislatures. State Medicaid Coverage of Weight-Loss Medications. January 2026.
13. UnitedHealthcare. Commercial Medical Benefit Drug Prior Authorization and Step Therapy Medication List. April 2026.
14. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. UnitedHealthcare is a registered trademark of UnitedHealth Group. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.